Patients with sickle cell disease (SCD) show a high prevalence of red blood cell (RBC) alloimmunization, but few studies have focused on children. We aimed to study the prevalence and risk factors of RBC alloimmunization in SCD children. We retrospectively analysed the medical and transfusion files for 245 SCD children hospitalized in our centre in 2014 and included 175 patients who had received at least one RBC unit in their lifetime. The main clinical and immuno-haematological characteristics of alloimmunized and non-alloimmunized patients were compared. The prevalence of alloimmunization was 13Á7% [95% confidence interval (CI) (8Á6-18Á6)], and 7Á4% [95% CI (3Á5-11Á3)] after excluding the probable irregular natural antibodies (anti-M, anti-Le a , anti-Le b , anti-Le x ). Main risk factors for alloimmunization were increased number of RBC units received (median of 65 vs. 10 units per patient; P = 0Á01) and the presence of one or more red cell autoantibodies (46Á2% vs. 4Á7%; P < 0Á0001). The alloimmunization rate was higher for episodically transfused than chronically transfused patients (1Á43 vs. 0Á24/100 units received; P < 0Á001). The presence of red cell autoantibodies appears to be a major risk factor for alloimmunization in SCD children and could justify specific transfusion guidelines.
Summary
Patients with sickle cell disease (SCD) show a high prevalence of red blood cell (RBC) alloimmunization, but few studies have focused on children. We aimed to study the prevalence and risk factors of RBC alloimmunization in SCD children. We retrospectively analysed the medical and transfusion files for 245 SCD children hospitalized in our centre in 2014 and included 175 patients who had received at least one RBC unit in their lifetime. The main clinical and immuno-haematological characteristics of alloimmunized and non-alloimmunized patients were compared. The prevalence of alloimmunization was 13Á7% [95% confidence interval (CI) (8Á6-18Á6)], and 7Á4% [95% CI (3Á5-11Á3)] after excluding the probable irregular natural antibodies (anti-M, anti-Le a , anti-Le b , anti-Le x ). Main risk factors for alloimmunization were increased number of RBC units received (median of 65 vs. 10 units per patient; P = 0Á01) and the presence of one or more red cell autoantibodies (46Á2% vs. 4Á7%; P < 0Á0001). The alloimmunization rate was higher for episodically transfused than chronically transfused patients (1Á43 vs. 0Á24/100 units received; P < 0Á001). The presence of red cell autoantibodies appears to be a major risk factor for alloimmunization in SCD children and could justify specific transfusion guidelines.
Keywords: sickle cell disease, children, blood transfusion, red blood cell alloimmunization, immunohaematology.
Red blood cell (RBC) transfusion is an essential treatment in the management of sickle cell disease (SCD) for both episodic or chronic indications (Estcourt et al, 2016) . Its main aims are the following: 1) increase the oxygen-carrying capacity in acute anaemia situations by increasing blood haemoglobin concentration 2) decrease the haemoglobin S proportion to prevent sickling secondary to polymerization of deoxyhaemoglobin S 3) restore blood flow in situations of vascular occlusion by replacing the stiff RBCs of the patient with deformable RBCs. Vichinsky et al (1990) reported that 90% of adults with SCD had received at least one RBC unit during their lifetime and the use of RBC transfusion in SCD has increased over time (Vichinsky et al, 1990; . Besides supply problems, viral transfusion risk, which is extremely low in high-income countries, and iron overload, transfusion of RBCs in SCD patients raises the major issue of alloimmunization and potentially life-threatening delayed haemolytic transfusion reactions (Yazdanbakhsh et al, 2012) . SCD patients show a high prevalence of RBC alloimmunization, ranging from 18% to 76% with ABO and D matching alone and about 20% in the most recent reviews (Chou et al, 2012; Zheng & Maitta, 2016) . The high rate is partly explained by the polymorphism of immunogenic blood group antigens and by significant phenotypic differences between blood donors, mostly of European descent, and patients of African descent (Vichinsky et al, 1990; Olujohungbe et al, 2001) . The high prevalence of partial antigens in patients and donors of African-Caribbean origin, especially in the Rh blood group system, appears to contribute to the high rate of alloimmunization in SCD patients despite an Rh (D,C,E,c,e)-Kell(K) phenocompatible transfusion strategy that has been implemented for several years in many countries (Chou et al, 2013) . Therefore, systematic genotyping of patients and donors is routinely performed in some centres (Casas et al, 2015) .
The main reported risk factors for RBC alloimmunization in SCD patients include age, age at first transfusion, number of RBC units received, autoantibody formation, increased research paper inflammation during transfusion and age of RBC units (Desai et al, 2015; Fasano et al, 2015; Nickel et al, 2015; Sins et al, 2016) . Evidence of an altered T H -cell response in alloimmunized patients is increasing, but the underlying immunological mechanisms remain incompletely understood (Bao et al, 2011; Vingert et al, 2014; Godefroy et al, 2016) . Few studies have focused on both chronically and episodically transfused paediatric patients (Wahl et al, 2012; Nickel et al, 2015) .
We aimed to study the prevalence and risk factors of RBC alloimmunization in a population of episodically or chronically transfused SCD children followed in our French university hospital reference centre.
Materials and methods

Study design
This single-centre retrospective cohort study was performed in a French university hospital SCD reference centre. Eligibility criteria were SCD of all types including SS, SC, S/b 0 and S/b + ; age ≤18 years at the time of hospitalization; hospitalization in Necker Hospital for Sick Children in 2014; and ≥1 RBC unit received during the lifetime followed by ≥1 RBC antibody screening at least 7 days after transfusion. The transfusion protocol applied in our centre, as in other French centres, since 1990 was that all patients received leucocyte-reduced, non-irradiated RBC units that were phenotypically matched for D, C/c, E/e and K. After alloimmunization, patients were supposed to receive RBC units that were also matched for the concerned antigens and for The medical and transfusion files of all patients were analysed, and information on transfusion history was obtained from the computerized blood transfusion databanks for the Paris area. If transfusions had been performed outside the Paris area, information on the number of RBC units received and the dates of transfusions was obtained from hospitalization reports. Medical files of patients followed in other centres were also systematically analysed. The following data were recorded: date of birth; gender; geographic origin; SCD type; follow-up in Necker Hospital for Sick Children or joint follow-up in another centre; basal haemoglobin level; number of hospitalizations for vaso-occlusive crisis, acute chest syndrome, splenic sequestration, stroke and osteomyelitis; number of RBC units received from birth to 31 December 2014; number of RBC units received from birth to positive RBC antibody screen; MET programme; indications and length of MET programme; results of RBC antibody screening; and any history of haemolytic transfusion reaction.
The primary outcome was alloimmunization. All patients underwent the same RBC antibody screening protocol, performed with a three-cell panel and a gel test technique (indirect antiglobulin test). If antibodies were detected, a 15-cell panel was used for their identification, completed when necessary with a 15-cell enzyme-treated RBC panel (papain and/ or trypsin). The distinction between alloantibodies and autoantibodies was based on the serological testing, RBC phenotyping and, when available, RBC genotyping (Ahrens et al, 2007; . Anti-M (anti-MNS1), anti-Le a (anti-LE1), anti-Le b (anti-LE2) and anti-Le x (anti-LE3) antibodies were considered naturally occurring antibodies if they were present before any transfusion. Otherwise, assessing whether these probable irregular natural IgM antibodies were not IgG alloantibodies was not possible because dithiothreitol (DTT) was not used and the so-called prewarm technique is not implemented in France. Therefore, patients were considered possibly alloimmunized and these antibodies were excluded for comparing proven alloimmunized and non-alloimmunized patients. The study was approved by the local Medical Ethics Committee.
Statistical analysis
The alloimmunization prevalence was calculated by dividing the number of alloimmunized patients by the total number of transfused patients who underwent RBC antibody screening at least 7 days after transfusion. The alloimmunization rate was calculated by dividing the number of alloimmunized patients by the total number of RBC units received (before first alloimmunization for alloimmunized patients and before 31 December 2014 for non-alloimmunized patients). An analysis of alloimmunization per RBC unit received was preferred to an analysis per transfusion event because each RBC unit from a different blood donor represents a specific exposure to different antigens and an additional risk for alloimmunization. The main clinical and immuno-haematological characteristics of alloimmunized and non-alloimmunized patients were compared by chi-square test or Fisher exact test and the Wilcoxon-Mann-Whitney test. We planned to perform multivariate multilevel analysis and adjust for cumulative exposure to RBC units by calculating Kaplan-Meier cumulative alloimmunization incidences with alloimmunization as the event and the cumulative number of transfused RBC units as a time variable (Sins et al, 2016) . However, the very low rate of alloimmunization did not allow such analyses.
Results
Patients
Among 250 children with SCD who were hospitalized in our centre in 2014, 182 had received at least one RBC transfusion in their lifetime, and seven were excluded from the analysis because the results of RBC antibody screening were not available after transfusion.
Among the 175 included patients, 164 (93Á7%) were homozygous HbSS, 8 (4Á6%) were HbS/ß 0 and 3 (1Á7%) were HbSC. The median age of patients in December 2014 was 11Á9 years [interquartile range (IQR): 7Á6-15Á4]. Patients were mainly of African (89%) and Caribbean origin (8%), the most frequent geographic origins being Congo (22%) and Cameroon (13%). The 175 patients received a median of 11 RBC units (range 1-339; IQR: 5-49) per patient. Overall, 75 patients (42Á9%) had been or were currently under a MET programme and received a total of 7184 RBC units, with a median of 61 units (IQR: 32-143) per patient. The median length of the MET programme was 3 years (IQR: 1Á7-4Á9). The main indications for the MET programme were primary stroke prevention (37Á7%), secondary stroke prevention (19Á5%), splenic sequestration prevention (27Á3%), acute chest syndrome and/or vaso-occlusive crisis prevention when hydroxycarbamide (also termed hydroxyurea) was not effective (13%). In all, 100 patients (57Á1%) were transfused only episodically for acute complications of SCD or for preoperative preparation and received a median of five RBC units (IQR: 2-9; total 653 RBC units) per patient. 78 patients (44Á6%) received hydroxycarbamide and 10 (5Á7%) had previously received hydroxycarbamide.
Among the 33 patients in whom red cell genotyping was performed, 6 (18Á2%) showed a partial antigen in the Rh blood group system: two patients had a partial D antigen (encoded by a RHD*weak partial 4Á0 allele), one patient had a partial C antigen (encoded by a RHCE*Ce-D(4)-Ce allele at the heterozygous state, included in the so-called R N haplotype) and three patients had a partial e antigen (encoded by the rare RHCE*ceAR allele for one patient and by the RHCE*ce667T allele, also named RHCE*ceMO, for two patients). Five patients (2Á9%) had an S-s-rare blood type (U+ var or U-).
RBC alloimmunization
Among the 175 patients with at least one transfusion in their lifetime, blood bank records for 38 (21Á7%) included a positive RBC antibody screen. Excluding autoantibodies and the naturally occurring antibodies identified before any transfusion, 24 patients were possibly alloimmunized. The prevalence of alloimmunization was 13Á7% [24/175, 95% confidence interval (CI) (8Á6-18Á6)], with an alloimmunization rate of 0Á35/100 units received. Anti-M was the most frequent antibody, encountered in 15 of 175 patients (8Á6%), before RBC transfusion in 6 (3Á4%) and after RBC transfusion in 9 (5Á1%). After excluding the probable irregular natural antibodies (anti-M, anti-Le a , anti-Le b , anti-Le x ), 13 patients had proven alloimmunization, with a prevalence of 7Á4% [13/175, 95% CI (3Á5-11Á3)] and an alloimmunization rate of 0Á19/100 units received (Fig 1) . These alloantibodies were directed against antigens of Rh (D, C, Ce and C (Fig 2) . Among the 24 possibly alloimmunized patients (including patients with a probable irregular natural antibody), 19 (79%) had a single RBC alloantibody, 3 (13%) had 2 alloantibodies and 2 (8%) had 3 or more alloantibodies. The median age at first alloimmunization was 5Á9 years (IQR: 3Á1-10Á6) but this increased to 8Á1 years (IQR: 4Á2-12Á9) when excluding the probable irregular natural antibodies. The median number of RBC units before first alloimmunization was 11 (IQR: 2-38), which increased to 19 (IQR: 9-63) when excluding the probable irregular natural antibodies. Among the three patients with delayed haemolytic transfusion reaction (DHTR), two showed an anti-M before the transfusion and received M-negative cross-matched units. After DHTR onset, no reaction was evidenced and the direct antiglobulin test was negative. A third patient with the phenotype D+C-E-c+e+,K-,Fy(a-b-),Jk(a+b+), S-s+ experienced DHTR after receiving three units, including two Fy(a+b+) units and one D+ unit. This patient was followed in our hospital and in another centre, where he was transfused without knowing his history of anti-D (partial D antigen encoded by RHD*weak partial 4Á0), anti-Fy3, anti-Kpa and anti-S antibodies.
Risk factors for alloimmunization
The clinical and immuno-haematological features for the 13 patients with proven RBC alloimmunization were compared to those for the 150 non-alloimmunized patients (the 11 patients with a probable irregular natural antibody and a patient in whom alloimmunization developed during the first months of 2015 were excluded from this analysis) (Table I) . On univariate analysis, statistically significant risk factors for alloimmunization were: the presence of one or more red cell autoantibodies (46Á2% vs. 4Á7%; P < 0Á0001), a higher number of RBC units received (median of 65 vs. 10 units per patient; P = 0Á01), a MET programme (76Á9% vs. 40Á0%; P = 0Á01) and a follow-up in two different centres (53Á8% vs. 22Á0%; P = 0Á02) ( Table I) . Median age at first transfusion was the same for alloimmunized and non-alloimmunized patients (3Á0 years; P = 0Á91) and the proportion with a first transfusion after age 5 years did not differ (30Á8% vs. 34Á7%; P = 1).
Including the probable irregular natural antibodies, the prevalence of alloimmunization for patients on a MET programme was 20Á0% [95% CI (10Á9-29Á1)] vs. 9Á0% [95% CI (3Á4-14Á6)] for patients who were only episodically transfused (P = 0Á04); the alloimmunization rate was 0Á24/100 vs. 1Á43/100 units received (P < 0Á001) and the median number of RBC units before first alloimmunization was 20 (IQR: 11-63) vs. 2 (IQR: 1-4) (P = 0Á003).
Excluding the probable irregular natural antibodies, the prevalence of alloimmunization for patients on a MET programme was 13Á3% [95% CI (5Á6-21)] vs. 3Á0% [95% CI (0-6Á3)] for patients who were only episodically transfused (P = 0Á02); the alloimmunization rate was 0Á16/100 vs. 0Á48/ 100 units received (P = 0Á11) and the median number of RBC units before first alloimmunization was 27 (IQR: 11-63) vs. 5 (IQR: 1-16) (P = 0Á05).
Discussion
In our study, the prevalence of RBC alloimmunization was 13Á7% when including the probable irregular natural antibodies and 7Á4% when these were excluded. The main risk factors for alloimmunization were an increased number of RBC units received and the presence of one or more red cell autoantibodies. The alloimmunization rate was higher for episodically than chronically transfused patients.
The relatively low frequency of alloimmunization compared to the expected 20% from the literature is probably due to the fact that our paediatric population received exclusive transfusions with blood systematically matched for C, c, E, e and K antigens and probably also other blood group antigens because the number of donors of AfricanCaribbean origin is rather high in the Paris region (Zheng & Maitta, 2016) . Indeed, most individuals of African-Caribbean origin are D+C-E-c+e+, but this phenotype is uncommon in people of European origin. The respect of the Rh/K phenotype suggests a significant likelihood of transfusion in intraethnic situations, which implies a higher probability of phenocompatibility in other blood group systems, such as Duffy, Kidd and MNS.
Anti-M was the most frequent antibody, with a prevalence of 5Á1%, whereas the prevalence of anti-Le a and anti-Le b antibodies was 2Á3% and 1Á7% respectively. This finding agrees with the results of a recent study in French Guiana, which reported anti-M, anti-Le a and anti-Le b antibodies to be the most frequent, with a prevalence of 3Á4%, 5Á6% and 2Á8%, respectively, among 178 SCD patients transfused mostly with blood from French European donors (Elenga & Niel, 2015) . These antibodies are usually irregular natural immunoglobulin M (IgM), but DTT was not used and the so-called pre-warm technique is not implemented in France. Therefore, it was not possible to determine whether they were not alloimmune IgG antibodies. Their evanescence was very fast and they probably appeared transiently in response to a non-specific immunological stimulation by a viral or bacterial infectious agent (Kao et al, 1978; Ishizaka et al, 1982; Das et al, 2014) . However, these antibodies should not be trivialized in the context of SCD, and it is highly recommended to transfuse SCD patients with blood matched for M and Le antigens when they have a history of anti-M or anti-Le antibodies.
Anti-Kpa (anti-KEL3) was present in 4 of 175 patients (2Á3%), but this alloantibody was not considered dangerous and did not justify specific transfusion guidelines. The antibodies of theoretical clinical significance identified in 9 of 175 patients (5Á1%) were directed against antigens of the Rh (D, C, Ce and C w ), Duffy (Fy a , Fy3), MNS (S, U) and Colton (Co b ) blood group systems. Red cell genotyping was performed after alloimmunization for all patients showing Rh alloantibodies. In our study, systematic red cell genotyping would probably have prevented the occurrence of the two anti-D alloimmunizations. The rate of Rh alloantibodies linked to a partial Rh phenotype was 5Á9% (2/34) among all alloantibodies produced and 11Á8% (2/17) when excluding the probable irregular natural antibodies, which is higher than that reported by some authors (Silvy et al, 2014) . Rh antibodies can be clinically significant in SCD patients with RH variants, and therefore allele matching in patients according to RH variants should be considered (Sippert et al, 2015) . The relatively high prevalence of partial antigens in the Rh blood group system suggests systematic performance of red cell genotyping for all SCD patients, as done in some centres (Casas et al, 2015) . Of interest, an anti-C antibody was found in a C-negative patient with multiple alloantibodies, who received only C-negative RBC units according to the French transfusion policy. This unexpected antibody could have appeared after transfusion of an RBC unit from a donor mistyped as C-negative, as may occur for some very weak C variants found in people of African origin (Pham et al, 2009) . This situation reflects the potential interest of performing red cell genotyping for blood donors (Casas et al, 2015) . This anti-C antibody could also correspond to a socalled mimicking alloantibody phenomenon, especially (Issitt et al, 1977) . The number of RBC units received was significantly higher in alloimmunized than non-alloimmunized patients, which could be expected because the frequency of alloimmunization is known to depend on the number of transfusions (Rosse et al, 1990; Zalpuri et al, 2012; Nickel et al, 2015) . The proportion of patients on a MET programme was also higher in the alloimmunized group and reflects the higher number of RBC units received, but the alloimmunization rate was significantly lower in patients on a MET programme than those episodically transfused (0Á24 vs. 1Á43/100 units received; P < 0Á001). This finding might be due to the fact that episodic transfusions are frequently performed in an inflammatory context (acute chest syndrome, severe vaso-occlusive crisis, worsening of anaemia in febrile context), and inflammation is a known risk factor for alloimmunization in SCD patients (Hendrickson et al, 2007; Fasano et al, 2015; Godefroy et al, 2016) . Similar results for episodic transfusions seeming to confer a higher alloimmunization risk as compared to chronic transfusions have been recently reported but without reaching statistical significance on multivariate analysis (Sins et al, 2016) .
The proportion of patients with one or more red cell autoantibodies was much higher in alloimmunized than nonalloimmunized patients (46Á2% vs. 4Á7%; P < 0Á0001). This result agrees with other literature data and suggests the presence of red cell autoantibodies as a major risk factor for alloimmunization (Ahrens et al, 2007; Nickel et al, 2015) .
Contrary to a recently report (Sins et al, 2016) , age at first transfusion did not appear to be a significant risk factor for alloimmunization in our cohort. Interestingly, among the patients for whom alloimmunization occurred during the MET programme, only one experienced alloimmunization in the first 6 months (2 months) and for the others, it occurred between 7 months and 4Á8 years after the start of the programme. This finding does not support alloimmunization always occurring early after initiation of an exchange transfusion programme even if patients with a responder phenotype are probably more prone to the development of alloantibodies (Sins et al, 2016) .
The comparison of alloimmunized and non-alloimmunized patients was limited by the small number of patients in the alloimmunized group. This lack of statistical power could explain the non-significant difference in sex ratio between the two groups, despite an apparent predominance of female patients in the alloimmunized group as compared with the non-alloimmunized group (69Á2% vs. 47Á3%; P = 0Á13). Indeed, female sex is a known risk factor for alloimmunization in the general population and in SCD patients but has not yet been reported in children (Campbell-Lee & Kittles, 2014; Verduin et al, 2015) . However, this risk factor might be limited to adult patients, considering the potential impact of pregnancy on alloimmunization. The small number of patients in the alloimmunized group is due in part to the fact that we chose not to include anti-M, anti-Le a , anti-Le b and anti-Le x antibodies because the alloimmune nature of these antibodies could not be assessed and they were very likely irregular natural antibodies. Our study might have featured selection bias because we did not include patients who were not hospitalized in 2014. Because their condition was probably less severe and they had possibly received fewer RBC units during their lifetime, the global prevalence of alloimmunization might have been overestimated. However, patients hospitalized in the day hospital for annual evaluation were included, and therefore our cohort was quite representative of the SCD paediatric population followed in our centre. The retrospective nature of our study might have implied measurement bias. We may have underestimated the number of previous transfusions, because some patients may have received blood transfusions outside the Paris region that were not recorded in their medical charts. However, this limitation should not have an impact on our results because it concerned alloimmunized as well as non-alloimmunized patients. Some alloimmunized patients might also have been misclassified as non-alloimmunized because RBC antibody screening was not performed at the same time after RBC transfusion for all patients and some alloantibodies might have become undetectable (Murao & Viana, 2005; Tormey & Stack, 2009 ). Finally, our study might feature confounding factors. Indeed, we found that a follow-up in two different centres was a statistically significant risk factor for alloimmunization but patients followed conjointly in another hospital and in our university hospital SCD reference centre may have had a more severe condition and received more RBC units than other patients. However, the example of the patient for whom RBC antibody screening had revealed poly-alloimmunization and who experienced a severe DHTR in another centre after a transfusion with a non-compatible RBC unit reflects the danger of such a noncentralized follow-up. This example also stresses the interest of centralizing immuno-haematological data for all patients by using shared medico-technical software.
In conclusion, the prevalence of RBC alloimmunization is relatively low among the SCD patients followed in our paediatric centre. Further improvements will require the implementation of systematic red cell genotyping in SCD patients and a careful transfusion strategy for those with red cell autoantibodies. the study. J.C. helped in the statistical analysis. T.P. helped in the interpretation of RBC antibody data. T.P. and D.A. and V.B. helped in the discussions. M.M. supervised the project.
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